Eli Lilly received FDA approval for a modified dosing regimen of its Alzheimer’s disease drug Kisunla designed to reduce the incidence of brain swelling, a serious adverse effect that has limited physician adoption. The slower dose ramp-up aims to enhance safety and improve patient tolerability, potentially boosting long-term utilization of the amyloid-targeting therapy. This regulatory update reflects Lilly's efforts to address risk management challenges associated with Kisunla.